publication . Article . 2020

Treatment of Patients with COVID-19 and Concomitant Cardiovascular Diseases: Do not Forget About the Principles of Evidence-based Medicine

S. Yu. Martsevich;
Open Access
  • Published: 01 May 2020 Journal: Rational Pharmacotherapy in Cardiology, volume 16, pages 273-276 (issn: 1819-6446, eissn: 2225-3653, Copyright policy)
  • Publisher: Stolichnaya Izdatelskaya Kompaniyaizdat
<jats:p>The recent discussion about the dangers of using angiotensin-converting-enzyme (ACE) inhibitors and angiotensin II receptor antagonists (ARA) in patients with COVID-19 is analyzed in the article. There is controversy over the hypothesis that these drugs can be factors contributing to an unfavorable outcome of a viral disease, as well as the absence of any clinical evidence for this hypothesis. The opinion that withdrawal of ACE inhibitors and ARA in patients with COVID-19 may increase the risk of adverse outcomes is presented.</jats:p>
Persistent Identifiers
Medical Subject Headings: food and beverages
free text keywords: covid-19, angiotensin converting enzyme inhibitors, angiotensin receptor antagonists, Therapeutics. Pharmacology, RM1-950, Diseases of the circulatory (Cardiovascular) system, RC666-701, Angiotensin receptor, Coronavirus disease 2019 (COVID-19), Viral disease, Bioinformatics, Angiotensin Receptor Antagonists, Medicine, business.industry, business, Adverse outcomes, Evidence-based medicine, Clinical evidence, Concomitant
Any information missing or wrong?Report an Issue